George Lundberg, MD Editor in Chief at Cancer Commons

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Approximately 20,000 Americans, mostly elderly, will be diagnosed with chronic lymphocytic leukemia (CLL) each year. There is no cure, but proper medication management can often provide 5 to 10 years of reasonable life. This practical 2019 discourse from Medscape is a reliable source.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Acute myeloid leukemia is a particularly difficult-to-treat form of leukemia. There are standard treatments, but it may be best for a patient to consider a clinical trial early on. This article from Medscape clearly specifies diagnostic and therapeutic options.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Acute lymphoblastic leukemia (also known as childhood leukemia) is a serious but often treatable form of leukemia. This authoritative presentation from Medscape is recent, trustworthy, and comprehensive.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Malignant melanoma is a fairly common, usually cutaneous, potentially lethal malignancy, and precision oncology has demonstrated some dramatic successes for treatment of its advanced stages. If you wish to learn more, this 2019 encyclopedic discourse from Medscape is solid, current, unbiased, and sensible.
  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Prostate cancer is the most common potentially lethal cancer diagnosed among American men. The great majority do not die of their disease. But there are many controversies about best handling. To learn more, read this authoritative, detailed presentation from Medscape, published August 2019.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Breast cancer is the most common potentially lethal cancer diagnosed among American women. The great majority are cured, but that does not mean that the topic is without disagreements. To learn more, read this authoritative, up-to-date, detailed presentation from Medscape.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Lung cancer kills more Americans than any other cancer. Often caused by tobacco smoking, it can also occur in non-smokers. To learn more, read this authoritative, up-to-date, in-depth, detailed, and comprehensive report on non-small cell lung cancer from Medscape.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Cancer of the urinary bladder is common, commonly recurs, and can be fatal. To learn more, read this up-to-date, comprehensive, unbiased, and balanced report from Medscape.
  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:

    Most prostate cancers don’t hurt the patient. Surgery for high-risk prostate cancer can be beneficial. If the cancer recurs, more treatment could be helpful. This study provides useful information about detection of recurrence.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

     

  •   George Lundberg, MD

    Excerpt from Cancer Network:

    “A deep learning approach to assessing cancer outcomes appears feasible, according to results of a study in patients with lung cancer. Machine curation yielded similarly accurate assessments of progression and times to improvement and response compared with human counterparts. This development could speed up oncology care processes.

    ” ‘Important clinical end points, such as response to therapy and disease progression, are often recorded in the EHR [electronic health record] only as unstructured text,’ wrote authors led by Kenneth L. Kehl, MD, MPH, of the Dana-Farber Cancer Institute in Boston. Standards such as RECIST are not routinely applied outside of clinical trials.”

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.